This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Carr E, Lerner S, Aultman R, Weisgerber-Kriegl U, Keating M.Treatment effect of first line rituximab, fludarabine and cyclosphosphamide in a chronic lymphocytic leukemia patient cohort: an evaluation of prognostic factors, estimated life expectany and economic outcomes. 50th Annual Meeting and Exposition of the American Society of Hematology: abstr. 2396, 7 Dec 2008. Available from: URL: http://www.hematology.org
Papadakis K, Oscier D, Carr ESC, Lewis G, Aultman R.A UK cost-effectiveness analysis comparing first line treatment with rituximab in combination with fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide alone in chronic lymphocytic leukemia patients. 50th Annual Meeting and Exposition of the American Society of Hematology: abstr. 2392, 7 Dec 2008. Available from: URL: http://www.hematology.org
Rights and permissions
About this article
Cite this article
R-FC cost effective for CLL on both sides of Atlantic. Pharmacoecon. Outcomes News 572, 10 (2009). https://doi.org/10.2165/00151234-200905720-00022
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905720-00022